These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 22186946)
1. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946 [TBL] [Abstract][Full Text] [Related]
2. Ex vivo reversal of the anticoagulant effects of edoxaban. Halim AB; Samama MM; Mendell J Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520 [TBL] [Abstract][Full Text] [Related]
3. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Elg M; Carlsson S; Gustafsson D Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338 [TBL] [Abstract][Full Text] [Related]
4. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219 [TBL] [Abstract][Full Text] [Related]
5. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432 [TBL] [Abstract][Full Text] [Related]
6. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645 [TBL] [Abstract][Full Text] [Related]
7. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats. Morishima Y; Honda Y; Kamisato C; Shibano T Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448 [TBL] [Abstract][Full Text] [Related]
8. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. Morishima Y; Kamisato C; Honda Y Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572 [TBL] [Abstract][Full Text] [Related]
9. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Dickneite G Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841 [TBL] [Abstract][Full Text] [Related]
10. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Perzborn E; Heitmeier S; Laux V; Buchmüller A Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498 [TBL] [Abstract][Full Text] [Related]
11. Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban. Honda Y; Furugohri T; Morishima Y Pharmacology; 2018; 101(1-2):92-95. PubMed ID: 29131074 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats. Shirasaki Y; Morishima Y; Shibano T Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349 [TBL] [Abstract][Full Text] [Related]
13. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Herzog E; Kaspereit F; Krege W; Doerr B; Mueller-Cohrs J; Pragst I; Morishima Y; Dickneite G Anesthesiology; 2015 Feb; 122(2):387-98. PubMed ID: 25419685 [TBL] [Abstract][Full Text] [Related]
14. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619 [TBL] [Abstract][Full Text] [Related]
15. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies. Lee FM; Chan AK; Lau KK; Chan HH Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649 [TBL] [Abstract][Full Text] [Related]
16. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents. Honda Y; Kamisato C; Morishima Y Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116 [TBL] [Abstract][Full Text] [Related]
17. Bleeding and antidotes in new oral anticoagulants. Majeed A; Schulman S Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907 [TBL] [Abstract][Full Text] [Related]
18. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. Morishima Y; Kamisato C; Honda Y; Furugohri T; Shibano T Thromb Res; 2013 Jan; 131(1):59-63. PubMed ID: 22999414 [TBL] [Abstract][Full Text] [Related]
19. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967 [TBL] [Abstract][Full Text] [Related]
20. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Martinowitz U; Livnat T; Zivelin A; Kenet G Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]